Esperion Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Esperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of nine analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -20 cents to -9 cents per share.

• Revenue rose 114.3% to $69.11 million from a year ago; analysts expected $61.58 million.

• Esperion Therapeutics Inc's reported EPS for the quarter was a loss of 11 cents​.

• The company reported a quarterly loss of $21.32 million.

• Esperion Therapeutics Inc shares had fallen by 28.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10.2% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.50

This summary was machine generated from LSEG data March 4 at 03:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)